Condition: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Sponsor: RemeGen Co., Ltd.
The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
This description comes directly from the study's public registry record.
Jianmin Fang, Ph.D · +8610-58075763 · Jianminfang@hotmail.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Yunnan Cancer Hospital | Kunming, Fujian, China | Not Yet Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| Gansu Wuwei Tumour Hospital | Wuwei, Gansu, China | Not Yet Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Nanfang Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Shandong Cancer Hospital & Institute | Jinan, Shangdong, China | Not Yet Recruiting |
| Sichuan Cancer Hospital & Institute | Chengdu, Sichuan, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06155383